Adaptive Biotechnologies Corp

For the period ended Sep 30, 2024. Filed Nov 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 7, 2024

ADPT$29.36-3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2024	2023	2024	2023
Revenue	$46,435	$37,919	$131,498	$124,492
Operating expenses
Cost of revenue	16,667	19,346	54,035	55,937
Research and development	24,163	28,533	79,761	93,371
Sales and marketing	20,551	20,493	63,184	66,673
General and administrative	17,258	20,075	54,750	63,208
Amortization of intangible assets	428	428	1,275	1,270
Impairment of long-lived assets	—	—	7,205	—
Total operating expenses	79,067	88,875	260,210	280,459
Loss from operations	(32,632)	(50,956)	(128,712)	(155,967)
Interest and other income, net	3,474	4,282	11,462	10,918
Interest expense	(2,939)	(3,652)	(8,628)	(10,788)
Net loss	(32,097)	(50,326)	(125,878)	(155,837)
Add: Net loss attributable to noncontrolling interest	26	26	78	28
Net loss attributable to Adaptive Biotechnologies Corporation	$(32,071)	$(50,300)	$(125,800)	$(155,809)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted	$(0.22)	$(0.35)	$(0.86)	$(1.08)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted	147,516,398	144,704,868	146,908,234	144,208,940

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.